[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nucana Plc ADR (NCNA)

Nucana Plc ADR (NCNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
NuCana Reports Promising Clinical Data for NUC-3373

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nucana (...

NCNA : 2.18 (+10.10%)
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Shares of Rallybio Corporation RLYB tanked 41.2% on April 8 after the company announced its decision to stop the development of RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia...

FOLD : 14.49 (+0.21%)
RLYB : 14.30 (+0.63%)
ANIP : 78.01 (-1.97%)
NCNA : 2.18 (+10.10%)
NuCana plc Reports Encouraging Clinical Data for NUC-7738 and NUC-3373, Highlights Financial Position and Future Milestones

NuCana reported encouraging results for NUC-7738 and NUC-3373 in recent clinical trials, with financial updates and a projected cash runway.Quiver AI SummaryNuCana plc announced encouraging Phase 2 results...

NCNA : 2.18 (+10.10%)
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022,...

NCNA : 2.18 (+10.10%)
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates...

NCNA : 2.18 (+10.10%)
NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification...

NCNA : 2.18 (+10.10%)
NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other...

NCNA : 2.18 (+10.10%)
NuCana to Participate in the 2022 Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host...

NCNA : 2.18 (+10.10%)

Barchart Exclusives

TTEC Stock Should Be on Your Radar as the Little-Known Company Quietly Builds Something Rivals Will Struggle to Copy
TTEC Holdings made a move that should matter to investors. Here is why this company looks increasingly hard to compete with. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.